This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cardiovascular disease				
Cardiovascular disease; neurology	Poly(ADR-ribose) polymerase-1 (PARP1; PARP-1)	<p>SAR studies identified a series of 4-carboxamidobenzimidazole PARP-1 inhibitors that could treat neurodegenerative diseases and cardiac ischemia. Screening led to the identification of a PARP-1 inhibitor with an IC_{50} of 14 nM and antioxidant properties preventing PARP-1's apoptotic function. Further studies of the compound's biological properties are ongoing.</p> <p>No fewer than six companies have inhibitors of PARP-1 in clinical and preclinical testing to treat cancer, cardiovascular disease and neurological conditions.</p> <p>SciBX 2(12); doi:10.1038/scibx.2009.492 Published online March 26, 2009</p>	Patent and licensing status unavailable	<p>Kálai, T. <i>et al. J. Med. Chem.</i>; published online Feb. 26, 2009; doi:10.1021/jm801476y</p> <p>Contact: Kálmán Hideg, University of Pecs, Pecs, Hungary e-mail: kalman.hideg@aok.pte.hu</p>